Craft

United Therapeutics

Stock Price

$352.8

2024-10-29

Market Capitalization

$15.7 B

2024-10-29

Revenue

$3.2 B

FY, 2025

United Therapeutics Summary

Company Summary

Overview
United Therapeutics is a biotechnology company that develops and manufactures pharmaceutical products for pulmonary arterial hypertension and certain cancers. It offers drugs including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, and develops technologies for organ transplantation such as xenotransplantation and organ manufacturing. The company serves medical institutions and healthcare providers involved in the treatment of pulmonary arterial hypertension, high-risk neuroblastoma, and organ transplantation.
Type
Public
Status
Active
Founded
1996
HQ
Silver Spring, MD, US | view all locations
Website
https://www.unither.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

LocationsView all

6 locations detected

  • Silver Spring, MD HQ

    United States

    1000 Spring St

  • Durham, NC

    United States

    55 TW Alexander Dr

  • Jacksonville, FL

    United States

  • Manchester, NH

    United States

  • Melbourne, FL

    United States

  • Washington, DC

    United States

United Therapeutics Financials

Summary Financials

Revenue (Q1, 2026)
$781.5M
Gross profit (Q1, 2026)
$648.1M
Net income (Q1, 2026)
$274.9M
Cash (Q1, 2026)
$1.3B
EBIT (Q1, 2026)
$325.8M

Footer menu